Moderna (MRNA) Shares Outstanding (Weighted Average) (2016 - 2026)

Moderna (MRNA) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $395.0 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $395.0 million, up 2.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $395.0 million (up 2.33% YoY), and the FY2025 annual result was $389.0 million, up 1.3% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $395.0 million in Q1 2026 per MRNA's latest filing, from $389.0 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $402.0 million in Q1 2022 and troughed at $381.0 million in Q2 2023.
• A 5-year average of $387.6 million and a median of $386.0 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Weighted Average) fell 3.98% in 2023, then increased 2.33% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $394.0 million in 2022, then declined by 3.05% to $382.0 million in 2023, then gained by 0.52% to $384.0 million in 2024, then increased by 1.3% to $389.0 million in 2025, then increased by 1.54% to $395.0 million in 2026.
• Business Quant data shows MRNA's Shares Outstanding (Weighted Average) at $395.0 million in Q1 2026, $389.0 million in Q4 2025, and $388.0 million in Q3 2025.